COMT, Methylation and Estrogen Clearance

The common variant, Val158Met, swaps one amino acid and produces an enzyme that is less heat-stable and works at a fraction of the capacity — a three- to four-fold difference between the two homozygous forms. Roughly a quarter of people of European ancestry carry two copies of the slower form, a quarter two copies of the faster, and half one of each. Like MTHFR, it is common enough that carrying it is not, on its own, a medical finding.

The variant's best-studied effects are on the brain, not on hormones. Because the slow form clears dopamine less quickly in the prefrontal cortex, carriers of the slow form perform slightly better on some cognitive tasks and show a somewhat larger stress response in laboratory studies — the "warrior/worrier" framing that has been popular in the press and is, in the primary literature, a small effect that is heavily modified by everything else. It is not a diagnosis of anxiety, and there is no trial in which a COMT genotype changed how anxiety was treated.

The hypothesis: a woman with the slow COMT form clears catechol estrogens less efficiently, accumulates more of the reactive 4-hydroxy metabolites, and is therefore at higher risk of estrogen-driven cancer — and should, on that basis, avoid hormone therapy, or "support methylation" to compensate.

What the evidence says: the mechanism is real in the laboratory. The clinical association has been tested many times, in case-control studies of COMT genotype and breast cancer risk, and the results are inconsistent — some studies found a modestly higher risk with the slow form, some found the opposite, and pooled analyzes have found no reliable association. No study has shown that COMT genotype changes the risk or benefit of hormone therapy, and no guideline uses it in the decision.

The functional-medicine extrapolation — that slow COMT is a reason to withhold HRT, or that methyl donors, magnesium and B vitamins "support COMT" and offset the risk — has no outcome evidence at all. It is a hypothesis being sold as a plan.

It tells you which version of an enzyme you carry. It does not tell you what the pathway is doing, because enzyme activity depends on far more than the gene: on the amount of substrate, on the availability of the methyl donor (which depends on the folate and B12 cycle the main page measures), on magnesium, on other enzymes competing for the same metabolites, and on the liver's other clearance routes. A woman with the slow genotype and a healthy methylation cycle may clear catechol estrogens perfectly well; one with the fast genotype and a depleted cycle may not.

That is the reason a measured metabolite profile — the DUTCH page — is more informative than the genotype, and the reason the genotype alone is not a basis for anything. Even the measured profile, as that page is careful to say, informs rather than decides.

Hormone therapy candidacy is decided on symptoms, personal and family history, the baseline panel and the guideline evidence on the women's HRT page. A COMT genotype is not among the inputs, and a woman who has been told her "slow COMT" means she cannot take estrogen has been told something no guideline body and no trial supports. Where a woman with a strong family history of breast cancer wants every available input, a measured metabolite profile is a reasonable thing to add to a careful conversation — as context. Her genotype is not even that.